Trends News Trends In Small Cell Lung Cancer Incidence And Survival

Imdelltra May Improve Survival in Small Cell Lung Cancer

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ... Read More

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ... Read More

Tarlatamab Improves Overall Survival in Small Cell Lung Cancer

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs standard of care therapy. Topline data were announced from a phase 3 trial ... Read More

Zocilurtatug Pelitecan Shows Potential in Small Cell Lung Cancer

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials. Read More

Lung Cancer Survival Has Improved in US, American Lung Association Report Shows

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ... Read More

A Chicago Grandmother’s Seven-Year Journey with Small-Cell Lung Cancer: A Fight for Time, Hope, and Progress

Maida Mangiameli, 75, has defied the odds by surviving over seven years with small-cell lung cancer—a disease with a five-year survival rate of just 5–10% according to the National Cancer Institute. Read More

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ... Read More

Defying the Odds With Small Cell Lung Cancer: Montessa Lee’s 19-Year Journey Is a Beacon of Hope

Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a historically low survival rate of just 5–10% according to the National ... Read More

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ... Read More

Characteristics and Associated Survival of Patients Diagnosed With Non–Small Cell Lung Cancer in a Designated Lung Cancer Program in Western Kenya

Two hundred forty-nine patients diagnosed with NSCLC were included with a median age at diagnosis of 61 (IQR, 52-70) years. Most patients were married (n = 177; 71%) and nonsmokers (n = 177; 71%) with ... Read More